Craft

BioNTech

Stock Price

$80.4

2024-06-28

Market Capitalization

$19.4 B

2024-06-28

Revenue

€3.8 B

FY, 2023

BioNTech Summary

Company Summary

Overview
BioNTech is a biotechnology company developing immunotherapies for cancer and infectious diseases. It combines research in immunology with a multi-technology innovation engine, GMP manufacturing, translational drug discovery, clinical development, commercial capabilities, computational medicine, data science and artificial intelligence, and machine learning capabilities.
Type
Public
Status
Active
Founded
2008
HQ
Mainz, DE | view all locations
Website
https://www.biontech.com/
Cybersecurity rating
Sectors

Key People

  • Ugur Sahin

    Ugur Sahin, Co-Founder and CEO

    • Jens Holstein

      Jens Holstein, Chief Financial Officer

    • Sean Marett

      Sean Marett, Chief Business and Chief Commercial Officer

    • Sierk Poetting

      Sierk Poetting, Chief Operating Officer

    Operating MetricsView all

    Phase I (Infectious Disease)

    3
    40.0%

    FY, 2023

    Pre-Clinical Phase (Infectious Disease)

    4
    50.0%

    FY, 2022

    Phase II (Oncology)

    8
    33.3%

    FY, 2023

    LocationsView all

    22 locations detected

    • Mainz, RP HQ

      Germany

      An d. Goldgrube 12

    • Cambridge, MA

      United States

      40 Erie St #110

    • Gaithersburg, MD

      United States

      930 Clopper Rd

    • San Francisco, CA

      United States

      650 California St Level 7

    • Melbourne, VIC

      Australia

      Level 17/570 Bourke St

    • Wien, Wien

      Austria

      Helmut-Qualtinger-Gasse 2

    and 16 others

    BioNTech Financials

    Summary Financials

    Revenue (Q1, 2024)
    €187.6M
    Gross profit (Q1, 2024)
    €178.0M
    Net income (Q1, 2024)
    (€315.1M)
    Cash (Q1, 2024)
    €9.0B
    EBIT (Q1, 2024)
    (€521.6M)
    Enterprise value
    $10.5B

    Footer menu